CRC Research Update

  • SCREENING

    Liquid biopsy detects residual disease after oligometastasis surgery

    A prospective multicenter study of 118 patients with resectable colorectal oligometastases found that combining pretreatment circulating tumor DNA genomic profiling with post-operative molecular residual disease (MRD) detection identified patients at highest risk of recurrence, with those positive for both markers showing a 13-fold higher risk. (ESMO Open)

  • LIVING WITH CRC

    Early-onset CRC shows distinct immune landscape

    A review in Cancer Immunology Research synthesizes evidence on the tumor-immune microenvironment of colorectal cancer diagnosed before age 50, highlighting differences in immune composition, functional states, and spatial organization that may inform prevention strategies and immunotherapy approaches for younger patients. (Cancer Immunol Res)

  • RESEARCH

    Review outlines strategies for identifying Lynch syndrome

    A review in Familial Cancer summarizes established and emerging approaches to Lynch syndrome detection in patients with colorectal neoplasia, noting that tumor-based mismatch repair testing remains cost-efficient but limited by incomplete implementation, while direct germline testing can identify additional hereditary syndromes. (Fam Cancer)

  • TREATMENT

    Pharmacokinetic method developed for pan-RAS inhibitor

    Researchers validated a mass spectrometry assay to measure daraxonrasib, an oral pan-RAS inhibitor in clinical evaluation for colorectal cancer, in canine plasma and whole blood, supporting pharmacokinetic characterization of the investigational drug. (Biomed Chromatogr)

Today's research spans liquid biopsy for post-surgical monitoring, immune features of early-onset disease, and genetic testing strategies for hereditary risk.